Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS Mutant Non-Small Cell Lung Cancer”

78 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 78 results

Testing effectiveness (Phase 2)Ended earlyNCT06024174
What this trial is testing

BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Who this might be right for
Advanced Solid Tumors
Bristol-Myers Squibb 5
Testing effectiveness (Phase 2)Active Not RecruitingNCT04699188
What this trial is testing

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Who this might be right for
KRAS G12C Mutant Solid TumorsCarcinoma, Non-Small-Cell LungCarcinoma, Colorectal+7 more
Novartis Pharmaceuticals 344
Testing effectiveness (Phase 2)Study completedNCT03704688
What this trial is testing

Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerKRAS Gene Mutation
Memorial Sloan Kettering Cancer Center 12
Testing effectiveness (Phase 2)UnknownNCT05451056
What this trial is testing

An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib

Who this might be right for
Non Small Cell Lung Cancer
Yonsei University 37
Large-scale testing (Phase 3)Looking for participantsNCT06890598
What this trial is testing

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company 700
Testing effectiveness (Phase 2)Study completedNCT01229150
What this trial is testing

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Who this might be right for
Non Small Cell Lung Carcinoma
National Cancer Institute (NCI) 89
Testing effectiveness (Phase 2)WithdrawnNCT05815186
What this trial is testing

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

Who this might be right for
Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
NYU Langone Health
Testing effectiveness (Phase 2)Looking for participantsNCT07148128
What this trial is testing

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

Who this might be right for
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic AdenocarcinomaAdvanced or Metastatic KRAS-mutant Tumor in Colorectal CancerAdvanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer+2 more
Auricula Biosciences Inc.
Testing effectiveness (Phase 2)Active Not RecruitingNCT05009329
What this trial is testing

JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

Who this might be right for
NSCLCSolid Tumor
Allist Pharmaceuticals, Inc. 315
Testing effectiveness (Phase 2)Looking for participantsNCT06128551
What this trial is testing

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Colorectal CancerPancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc. 534
Early research (Phase 1)Study completedNCT02022982
What this trial is testing

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Who this might be right for
KRAS Mutant Non-Small Cell Lung CancerSolid Tumors
Dana-Farber Cancer Institute 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06456138
What this trial is testing

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Who this might be right for
KRAS Mutation-Related TumorsAdvanced Lung CancerRefractory Tumor
Shanghai Chest Hospital 60
Testing effectiveness (Phase 2)Study completedNCT01951690
What this trial is testing

Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerLung Cancer
Verastem, Inc. 55
Testing effectiveness (Phase 2)Active Not RecruitingNCT05375994
What this trial is testing

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

Who this might be right for
Non Small Cell Lung CancerKRAS Activating MutationAdvanced Cancer+3 more
Verastem, Inc. 85
Testing effectiveness (Phase 2)Ended earlyNCT03095612
What this trial is testing

Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
University of Texas Southwestern Medical Center 41
Early research (Phase 1)Ended earlyNCT03948763
What this trial is testing

MRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)

Who this might be right for
NeoplasmsCarcinoma, Non-Small-Cell LungPancreatic Neoplasms+1 more
Merck Sharp & Dohme LLC 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT05358249
What this trial is testing

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Who this might be right for
KRAS G12C Mutant Solid TumorsCarcinoma, Non-Small Cell LungCarcinoma, Non-Small-Cell Lung+8 more
Novartis Pharmaceuticals 74
Testing effectiveness (Phase 2)Study completedNCT06333678
What this trial is testing

A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center 10
Large-scale testing (Phase 3)Looking for participantsNCT07554339
What this trial is testing

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 310
Testing effectiveness (Phase 2)Study completedNCT04620330
What this trial is testing

Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerKRAS Activating Mutation
Verastem, Inc. 90
Load More Results
110